A5065196329- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Cancer Genomics and Diagnostics
- RNA modifications and cancer
- Colorectal Cancer Treatments and Studies
- Lymphoma Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- Gastric Cancer Management and Outcomes
- Neuroendocrine Tumor Research Advances
- Genetic factors in colorectal cancer
- Radiomics and Machine Learning in Medical Imaging
- Viral-associated cancers and disorders
- Cancer-related molecular mechanisms research
- Medical Imaging and Pathology Studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- HER2/EGFR in Cancer Research
- Cancer-related gene regulation
- Cancer Immunotherapy and Biomarkers
- Salivary Gland Tumors Diagnosis and Treatment
- Gastrointestinal Tumor Research and Treatment
- Sarcoma Diagnosis and Treatment
- Cancer Diagnosis and Treatment
- Metastasis and carcinoma case studies
- Epigenetics and DNA Methylation
Tokyo National Hospital
2019-2025
National Cancer Center Hospital East
2021-2025
Juntendo University
2023-2024
National Cancer Center
2020-2024
John Wiley & Sons (Germany)
2024
Taipei Veterans General Hospital
2024
National Yang Ming Chiao Tung University
2024
International Association for the Study of Lung Cancer
2024
Aichi Cancer Center
2013-2023
National Hospital Organization Kyushu Cancer Center
2022
Abstract In this study, we report for the first time reduced expression of let-7 microRNA in human lung cancers. Interestingly, 143 cancer cases that had undergone potentially curative resection could be classified into two major groups according to unsupervised hierarchical analysis, showing significantly shorter survival after with (P = 0.0003). Multivariate COX regression analysis showed prognostic impact independent disease stage (hazard ratio 2.17; P 0.009). addition, overexpression...
MicroRNAs (miRNAs) are small noncoding RNAs, thought to be involved in physiologic and developmental processes by negatively regulating expression of target genes. We have previously reported frequent down-regulation the let-7 miRNA family lung cancers and, present study, assessed alteration a panel 19 cancer cell lines. As result, we found for first time that miR-17-92 cluster, which comprises seven miRNAs resides intron 3 C13orf25 gene at 13q31.3, is markedly overexpressed cancers,...
Abstract Recently it has been reported that mutations in the tyrosine kinase domain of epidermal growth factor receptor(EGFR) gene occur a subset patients with lung cancer showing dramatic response to EGFR inhibitors. To gain further insights role carcinogenesis, we sequenced exons 18–21 using total RNA extracted from unselected 277 who underwent surgical resection and correlated results clinical pathologic features. were present 111 (40%). Fifty-two in-frame deletions around codons 746–750...
The EML4 (echinoderm microtubule-associated protein-like 4)-ALK (anaplastic lymphoma kinase) fusion-type tyrosine kinase is an oncoprotein found in 4 to 5% of non-small-cell lung cancers, and clinical trials specific inhibitors ALK for the treatment such tumors are currently under way. Here, we report discovery two secondary mutations within domain EML4-ALK tumor cells isolated from a patient during relapse phase with inhibitor. Each mutation developed independently subclones conferred...
Purpose To evaluate the relationship between mutations of epidermal growth factor receptor (EGFR) gene and effectiveness gefitinib treatment in patients with recurrent lung cancer after pulmonary resection. Patients Methods We sequenced exons 18-21 EGFR using total RNA extracted from 59 who were treated for cancer. Gefitinib was evaluated by both imaging studies change serum carcinoembryonic antigen (CEA) levels. Results found 33 (56%). Of these mutations, 17 deletions around codons 746-750...
Context.— In 2013, an evidence-based guideline was published by the College of American Pathologists, International Association for Study Lung Cancer, and Molecular Pathology to set standards molecular analysis lung cancers guide treatment decisions with targeted inhibitors. New evidence has prompted evaluation additional laboratory technologies, targetable genes, patient populations, tumor types testing. Objective.— To systematically review update 2013 affirm its validity; assess new...
Abstract Lung cancer with epidermal growth factor receptor (EGFR)–activating mutations responds favorably to the EGFR tyrosine kinase inhibitors gefitinib and erlotinib. However, 25% 30% of patients EGFR-activating show intrinsic resistance, responders invariably acquire resistance gefitinib. Here, we showed that hepatocyte (HGF), a ligand MET oncoprotein, induces lung adenocarcinoma cells by restoring phosphatidylinositol 3-kinase/Akt signaling pathway via phosphorylation MET, but not or...
Emerging evidence suggests that microRNA, which are well‐conserved, abundant and small regulatory RNA, may be involved in the pathogenesis of human cancers. We recently reported expression let ‐7 was frequently reduced lung cancers, significantly associated with shorter patient survival. Two members double‐stranded RNA‐specific endonuclease family, Dicer Drosha , convert precursor forms microRNA into their mature using a stepwise process. In present study, we examined levels these genes 67...
Abstract Purpose: Non–small cell lung cancers carrying activating mutations in the gene for epidermal growth factor receptor (EGFR) are highly sensitive to EGFR-specific tyrosine kinase inhibitors. However, most patients who initially respond subsequently experience disease progression while still on treatment. Part of this “acquired resistance” is attributable a secondary mutation resulting threonine methionine at codon 790 (T790M) EGFR. Experimental Design: We sequenced exons 18 21 EGFR...
The new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification provides, first time, standardized terminology cancer diagnosis in small biopsies and cytology; this was not primarily addressed by previous World Health Organization classifications. Until recently there have been no therapeutic implications to further NSCLC, so little attention has given distinction squamous cell carcinoma tissue samples....
Activating mutation of KRAS and BRAF are focused on as potential prognostic predictive biomarkers in patients with colorectal cancer (CRC) treated anti-EGFR therapies. This study investigated the clinicopathological features impact KRAS/BRAF advanced recurrent CRC patients. Patients systemic chemotherapy (n=229) were analysed for genotypes by cycleave PCR. Prognostic factors associated survival identified univariate multivariate analyses using Cox proportional hazards model. mutations...